- Home
- DOUG vs BIOA Comparison
DOUG vs BIOA Comparison
Compare DOUG & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- BIOA
- Stock Information
- Founded
- DOUG 1911
- BIOA 2015
- Country
- DOUG United States
- BIOA United States
- Employees
- DOUG N/A
- BIOA N/A
- Industry
- DOUG Building operators
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- BIOA Health Care
- Exchange
- DOUG Nasdaq
- BIOA Nasdaq
- Market Cap
- DOUG 161.5M
- BIOA 139.8M
- IPO Year
- DOUG N/A
- BIOA 2024
- Fundamental
- Price
- DOUG $2.61
- BIOA $4.34
- Analyst Decision
- DOUG
- BIOA Hold
- Analyst Count
- DOUG 0
- BIOA 4
- Target Price
- DOUG N/A
- BIOA $5.67
- AVG Volume (30 Days)
- DOUG 1.3M
- BIOA 348.2K
- Earning Date
- DOUG 08-06-2025
- BIOA 08-15-2025
- Dividend Yield
- DOUG N/A
- BIOA N/A
- EPS Growth
- DOUG N/A
- BIOA N/A
- EPS
- DOUG N/A
- BIOA N/A
- Revenue
- DOUG $1,048,791,000.00
- BIOA $1,451,000.00
- Revenue This Year
- DOUG $17.61
- BIOA N/A
- Revenue Next Year
- DOUG N/A
- BIOA N/A
- P/E Ratio
- DOUG N/A
- BIOA N/A
- Revenue Growth
- DOUG 11.36
- BIOA N/A
- 52 Week Low
- DOUG $1.03
- BIOA $2.88
- 52 Week High
- DOUG $3.20
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- DOUG 54.35
- BIOA N/A
- Support Level
- DOUG $2.60
- BIOA N/A
- Resistance Level
- DOUG $3.00
- BIOA N/A
- Average True Range (ATR)
- DOUG 0.16
- BIOA 0.00
- MACD
- DOUG -0.04
- BIOA 0.00
- Stochastic Oscillator
- DOUG 20.49
- BIOA 0.00
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.